| Ident. | Authors (with country if any) | Title |
|---|
| 000011 (2021) |
Matthieu Million [France] ; Audrey Giraud-Gatineau [France] ; Jean-Christophe Lagier [France] ; Philippe Parola [France] ; Philippe Gautret [France] ; Didier Raoult [France] | Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin. |
| 000015 (2021) |
Roberto Ariel Abelda O Zu Iga [Mexique] ; Silvia Mercedes Coca [Mexique] ; Giuliana Florencia Abelda O [Mexique] ; Ruth Ana María González-Villoria [Mexique] | Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. |
| 000016 (2021) |
Claudia Lilli ; Annibale Biggeri [Italie] ; Chiara Zingaretti ; Bernadette Vertogen ; Valeria Frassineti ; Roberto Vespignani ; Veruska Grossi ; Caterina Florescu ; Laura Matteucci ; Chiara Pazzi ; Alberto Bongiovanni ; Francesco Limarzi ; Valentina Fausti ; Lucia Bertoni ; Caterina Donati ; Francesca Galardi ; Nicola Gentili ; Francesco Mazza ; Giovanni Martinelli ; Oriana Nanni | Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. |
| 000027 (2021) |
S. Ortonobes Roig [Espagne] ; N. Soler-Blanco ; I. Torrente Jiménez ; E. Van Den Eynde Otero ; M. Moreno-Ari O ; M. G Mez-Valent | [Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients]. |
| 000028 (2021) |
X S Wang [République populaire de Chine] ; J H Cai [République populaire de Chine] ; M. Zeng [République populaire de Chine] ; H. Tian [République populaire de Chine] ; H L Chang [République populaire de Chine] ; Y L Ge [République populaire de Chine] ; J J Li [République populaire de Chine] ; Z Q Wei [République populaire de Chine] ; J S Wang [République populaire de Chine] | [Clinical analysis of liver chemistries in children and adolescent with 2019-nCoV infection]. |
| 000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
| 000046 (2021) |
Paulo Roberto Bignardi [Brésil] ; Carolina Santos Vengrus [Brésil] ; Bruno Matos Aquino [Brésil] ; Alcindo Cerci Neto [Brésil] | Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. |
| 000060 (2021) |
Diana Laila Ramatillah [Indonésie] ; Suri Isnaini [Indonésie] | Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. |
| 000084 (2021) |
Bhanu Prasad Venkatesulu [États-Unis] ; Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Prashanth Giridhar [Inde] ; Pragathee V [Inde] ; Harsh K. Patel [États-Unis] ; Jacob Manteuffel [États-Unis] | The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review. |
| 000095 (2021) |
Po-Liang Chen [République populaire de Chine] ; Yi-Han Hsiao [République populaire de Chine] ; Chien Chuang [République populaire de Chine] ; Jia-Yih Feng [République populaire de Chine] ; Hsiang-Ling Ho [République populaire de Chine] ; Yi-Tsung Lin [République populaire de Chine] ; Su-Jung Chen [République populaire de Chine] ; Shiang-Fen Huang [République populaire de Chine] ; Hsin-Pai Chen [République populaire de Chine] ; Teh-Ying Chou [République populaire de Chine] ; Yuh-Min Chen [République populaire de Chine] ; Fu-Der Wang [République populaire de Chine] | The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. |
| 000105 (2021) |
Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban] | The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. |
| 000137 (2021) |
Ça La Begüm Apayd N [Turquie] ; Gözde Ç Nar [Turquie] ; Gökçe Cihan-Üstünda [Turquie] | Small-molecule antiviral agents in ongoing clinical trials for COVID-19. |
| 000155 (2021) |
Alberto Enrico Maraolo [Italie] ; Adriano Grossi [Italie] | Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. |
| 000160 (2021) |
Saeidreza Jamalimoghadamsiahkali [Iran] ; Besharat Zarezade [Iran] ; Sogol Koolaji [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Abolfazl Zendehdel [Iran] ; Mohammad Tabarestani [Iran] ; Ehsan Sekhavati Moghadam [Iran] ; Ladan Abbasian [Iran] ; Seyed Ali Dehghan Manshadi [Iran] ; Mohamadreza Salehi [Iran] ; Malihe Hasannezhad [Iran] ; Sara Ghaderkhani [Iran] ; Mohsen Meidani [Iran] ; Faeze Salahshour [Iran] ; Fatemeh Jafari [Iran] ; Navid Manafi [Canada] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. |
| 000169 (2021) |
Bianca D. Balmant [Brésil] ; Raquel S. Torrinhas [Brésil] ; Ilanna M. Rocha [Brésil] ; Danielle C. Fonseca [Brésil] ; Francisco F C. Formiga [Brésil] ; Eloisa S D O. Bonfá [Brésil] ; Eduardo F. Borba [Brésil] ; Dan L. Waitzberg [Brésil] | SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link? |
| 000190 (2021) |
Dingzhong Li [République populaire de Chine] ; Jianbing Hu [République populaire de Chine] ; Dian Li [République populaire de Chine] ; Weijun Yang [République populaire de Chine] ; Shuang-Feng Yin [République populaire de Chine] ; Renhua Qiu [République populaire de Chine] | Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. |
| 000195 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000211 (2021) |
Sebastian E. Sattui [États-Unis] ; Elizabeth R. Graef [États-Unis] ; Jean W. Liew [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Alfred H J. Kim [États-Unis] | Reply to 'Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science'. |
| 000218 (2021) |
Marcelo Rodrigues Dos Santos [Brésil] | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. |
| 000276 (2021) |
Nida Bokharee [Pakistan] ; Yusra Habib Khan ; Aisha Khokhar [Pakistan] ; Tauqeer Hussain Mallhi ; Nasser Hadal Alotaibi ; Maria Rasheed [Pakistan] | Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. |
| 000279 (2021) |
Osama A. Badary [Égypte] | Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. |
